Alzheimer's Disease Therapeutics and Diagnostics Market (Updated Version Available)

Overview Of Alzheimers Disease Therapeutics and Diagnostics Market

Alzheimer\'s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer\'s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer\'s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimers disease. One in nine people aged 65 and above has Alzheimers disease. By 2050, the number of people aged 65 and above affected with Alzheimers disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer\'s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer\'s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer\'s therapeutics and diagnostics worldwide.

Population aging across the globe is a major factor driving the market for Alzheimer\'s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand. The New Alzheimers Disease Therapeutics and Diagnostics Market Research Analysis provides a detailed overview, Shares, Strategy, and Forecasts of the Alzheimers Disease Therapeutics and Diagnostics market and delivers a comprehensive individual analysis on the top companies, including Namenda, Aricept, Exelon, Solanezumab, Gantenerumab, Verubecestat, Pfizer, Eisai, Actavis, Lundbeck, Daiichi Sankyo, Novartis, TauRx

The Alzheimers Disease Therapeutics and Diagnostics market is anticipated to grow at a CAGR of about XX% over the forecast period, i.e., 2021-2028. The market is expected to reach USD XX million by the end of 2028.

The report provides valuable data on global Alzheimers Disease Therapeutics and Diagnostics industry. Present and historical as well as future trends of global and countries markets are considered. Also Report complete study of current trends in the Alzheimers Disease Therapeutics and Diagnostics market, industry growth drivers, and restraints. It provides Alzheimers Disease Therapeutics and Diagnostics market projections for the coming years. It includes analysis of recent developments in technology, Porter\'s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Key Companies
Namenda

Aricept

Exelon

Solanezumab

Gantenerumab

Verubecestat

Pfizer

Eisai

Actavis

Lundbeck

Daiichi Sankyo

Novartis

TauRx

Market Product Type Segmentation
Biomarkers

Cholinesterase inhibitors

NMDA receptor antagonists

Brain imaging

Blood tests

Market by Application Segmentation
Drugs Market

Diagnostics Market

By Region
Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America [United States, Canada, Mexico]
Middle East & Africa [GCC, North Africa, South Africa]
South America [Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the size of occupied by the prominent leaders for the forecast period, 2021 to 2028?
• What will be the share and the growth rate of the Alzheimers Disease Therapeutics and Diagnostics market during the forecast period?
• What are the future prospects for the Alzheimers Disease Therapeutics and Diagnostics industry in the coming years?
• Which trends are likely to contribute to the development rate of the industry during the forecast period, 2021 to 2028?
• What are the future prospects of the Alzheimers Disease Therapeutics and Diagnostics industry for the forecast period, 2021 to 2028?
• Which companies are dominating the competitive landscape across different region and what strategies have they applied to gain a competitive edge?
• What are the major factors responsible for the growth of the market across the different regions?
• What are the challenges faced by the companies operating in the Alzheimers Disease Therapeutics and Diagnostics market?

Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.